These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 25250768

  • 1. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.
    Chowdhary A, Kathuria S, Singh PK, Sharma B, Dolatabadi S, Hagen F, Meis JF.
    Mycoses; 2014 Dec; 57 Suppl 3():97-107. PubMed ID: 25250768
    [Abstract] [Full Text] [Related]

  • 2. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.
    Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1745-50. PubMed ID: 25583714
    [Abstract] [Full Text] [Related]

  • 3. The environmental source of emerging Apophysomyces variabilis infection in India.
    Prakash H, Ghosh AK, Rudramurthy SM, Paul RA, Gupta S, Negi V, Chakrabarti A.
    Med Mycol; 2016 Aug 01; 54(6):567-75. PubMed ID: 27118802
    [Abstract] [Full Text] [Related]

  • 4. A prospective study of mucormycosis in north India: experience from a tertiary care hospital.
    Bala K, Chander J, Handa U, Punia RS, Attri AK.
    Med Mycol; 2015 Apr 01; 53(3):248-57. PubMed ID: 25587084
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles.
    Wagner L, de Hoog S, Alastruey-Izquierdo A, Voigt K, Kurzai O, Walther G.
    Antimicrob Agents Chemother; 2019 Aug 01; 63(8):. PubMed ID: 31182532
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order.
    Arendrup MC, Jensen RH, Meletiadis J.
    Antimicrob Agents Chemother; 2015 Dec 01; 59(12):7735-42. PubMed ID: 26438494
    [Abstract] [Full Text] [Related]

  • 11. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
    Riley TT, Muzny CA, Swiatlo E, Legendre DP.
    Ann Pharmacother; 2016 Sep 01; 50(9):747-57. PubMed ID: 27307416
    [Abstract] [Full Text] [Related]

  • 12. COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
    Abdorahimi M, Pakdel F, Salehi M, Alcazar-Fuoli L, Hashemi SJ, Daie Ghazvini R, Ahmadkhani F, Ahmadikia K, Abdollahi A, Debran JCS, Tabari A, Farrokh F, Mousavand A, Afarinesh Khaki P, Salami Khaneshan A, Ibrahim AS, Khodavaisy S.
    Mycopathologia; 2023 Oct 01; 188(5):783-792. PubMed ID: 37672164
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.
    Vidal P, Schwarz P, Dannaoui E.
    Antimicrob Agents Chemother; 2019 Oct 01; 63(10):. PubMed ID: 31358578
    [Abstract] [Full Text] [Related]

  • 14. Two new species of Mucor from clinical samples.
    Alvarez E, Cano J, Stchigel AM, Sutton DA, Fothergill AW, Salas V, Rinaldi MG, Guarro J.
    Med Mycol; 2011 Jan 01; 49(1):62-72. PubMed ID: 20662633
    [Abstract] [Full Text] [Related]

  • 15. Rapid screening for human-pathogenic Mucorales using rolling circle amplification.
    Dolatabadi S, Najafzadeh MJ, de Hoog GS.
    Mycoses; 2014 Dec 01; 57 Suppl 3():67-72. PubMed ID: 25187214
    [Abstract] [Full Text] [Related]

  • 16. Fungal necrotizing fasciitis, an emerging infectious disease caused by Apophysomyces (Mucorales).
    Chander J, Stchigel AM, Alastruey-Izquierdo A, Jayant M, Bala K, Rani H, Handa U, Punia RS, Dalal U, Attri AK, Monzon A, Cano-Lira JF, Guarro J.
    Rev Iberoam Micol; 2015 Dec 01; 32(2):93-8. PubMed ID: 25576377
    [Abstract] [Full Text] [Related]

  • 17. In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales.
    Schwarz P, Schwarz PV, Felske-Zech H, Dannaoui E.
    J Antimicrob Chemother; 2019 Jul 01; 74(7):1921-1927. PubMed ID: 30934052
    [Abstract] [Full Text] [Related]

  • 18. Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus.
    Rudramurthy SM, Singh S, Kanaujia R, Chaudhary H, Muthu V, Panda N, Pandey A, Thakur S, Kaur H, Ghosh A, Agarwal R, Chakrabarti A.
    Emerg Infect Dis; 2023 Jul 01; 29(7):1313-1322. PubMed ID: 37347535
    [Abstract] [Full Text] [Related]

  • 19. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.
    Vitale RG, de Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, Voigt K, van de Sande WW, Dolatabadi S, Meis JF, Walther G.
    J Clin Microbiol; 2012 Jan 01; 50(1):66-75. PubMed ID: 22075600
    [Abstract] [Full Text] [Related]

  • 20. Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis.
    Gupta P, Malhotra HS, Saxena P, Singh R, Shukla D, Hasan MS, Verma V, Banerjee G, Puri B, Dandu H.
    J Investig Med; 2022 Apr 01; 70(4):914-918. PubMed ID: 35078866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.